Octreotide LAR and Tamoxifen Versus Tamoxifen in Phase III Randomize Early Breast Cancer Trials: NCIC CTG MA.14 and NSABP B-29

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-015-3547-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Osteoporosis Therapy and Outcomes for Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer: NCIC CTG MA.27

Cancer
Cancer ResearchOncology
2017English

Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Octreotide and Tamoxifen in Combination Increase Survival Time of Patients With Pancreatic Cancer

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1995English

A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors Versus Tamoxifen in Early Stage Breast Cancer

PLoS ONE
Multidisciplinary
2013English

Use of Tamoxifen and Raloxifene for Breast Cancer Chemoprevention in 2010

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Tamoxifen and Mastectomy for Elderly Patients With Operable Breast Cancer.

BMJ
1988English

Ovarian Cysts in Women Receiving Tamoxifen for Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1999English

Oxidative Stress Contributes to the Tamoxifen-Induced Killing of Breast Cancer Cells: Implications for Tamoxifen Therapy and Resistance

Scientific Reports
Multidisciplinary
2016English

Effect of Anastrozole and Tamoxifen on Lipid Metabolism in Japanese Postmenopausal Women With Early Breast Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy